Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.

Humans Small Cell Lung Carcinoma / drug therapy Lung Neoplasms / pathology Antineoplastic Combined Chemotherapy Protocols / adverse effects Antibodies, Monoclonal, Humanized / adverse effects

Atezolizumab PD-L1 Small cell lung cancer İmmunotherapy

Journal

Journal of cancer research and clinical oncology

ISSN: 1432-1335

Titre abrégé: J Cancer Res Clin Oncol

Pays: Germany

ID NLM: 7902060

Informations de publication

Date de publication:
Dec 2022

Historique:

received: 11 03 2022

accepted: 22 05 2022

pubmed: 11 6 2022

medline: 26 10 2022

entrez: 10 6 2022

Statut: ppublish

Résumé

Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

Identifiants

DOI: 10.1007/s00432-022-04087-x PMID: 35689097

pubmed: 35689097

doi: 10.1007/s00432-022-04087-x

pii: 10.1007/s00432-022-04087-x

doi:

Substances chimiques

atezolizumab 52CMI0WC3Y

Antibodies, Monoclonal, Humanized 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

3547-3555

Informations de copyright

Références

Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121(5):664–672

doi: 10.1002/cncr.29098

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JH, Kao S, Miller WH Jr et al (2020) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15(4):618–627

doi: 10.1016/j.jtho.2019.12.109

Farago AF, Keane FK (2018) Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 7(1):69

doi: 10.21037/tlcr.2018.01.16

Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi99–vi105

doi: 10.1093/annonc/mdt178

Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737

doi: 10.1038/nrc.2017.87

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2021) Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22(1):51–65

doi: 10.1016/S1470-2045(20)30539-8

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

doi: 10.1056/NEJMoa1809064

Huang L, Shi Y (2020) Prognostic value of pretreatment smoking status for small cell lung cancer: a meta-analysis. Thoracic Cancer 11(11):3252–3259

doi: 10.1111/1759-7714.13661

Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC et al (2021) Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03052-w

doi: 10.1007/s00262-021-03052-w pubmed: 34816323 pmcid: 9016021

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

doi: 10.1016/S0140-6736(19)32222-6

Pietanza MC, Byers LA, Minna JD, Rudin CM (2015) Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21(10):2244–2255

doi: 10.1158/1078-0432.CCR-14-2958

Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748

doi: 10.1200/JCO.2016.67.6601

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T et al (2020) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 38(21):2369

doi: 10.1200/JCO.20.00793

Sahin AB, Cubukcu E, Ocak B, Deligonul A, Kacan T, Orhan SO et al (2020) Chemo-immunotherapy with atezolizumab in extensive-stage small-cell lung cancer; Single-Center Experience. Int J Hematol Oncol. https://doi.org/10.4999/uhod.204252

doi: 10.4999/uhod.204252

Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV et al (2020) Association of sex, age, and Eastern Cooperative Oncology Group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open 3(8):e2012534

doi: 10.1001/jamanetworkopen.2020.12534